The Franklin Lakes, N.J.-based healthcare giant said it expects to post adjusted earnings per share of $2.70 on sales of $4.16 billion for the three months ended Dec. 31, 2018. Analysts on The Street were looking for adjusted EPS of $2.61 on sales of $4.11 billion.
The company chalked up the earnings gain to “the timing of certain tax items, as well as better-than-expected performance across all three segments.”
BD said the adjusted EPS gain amounted to 8.9%, or 14.9% on a constant-currency basis, with sales up 35.1% compared with fiscal Q1 2018, “primarily due to the acquisition of C. R. Bard.” Fiscal Q1 revenues were up 5.2% compared with the same period last year on a constant-currency basis that includes Bard sales, the company said.
For the full fiscal year, BD said it still expects to report adjusted EPS of $12.05 to $12.15, representing growth of roughly 10.0% compared with fiscal 2018. Full-year sales growth is still pegged at 8.5% to 9.5%, primarily due to the Bard buyout, or 5.0% to 6.0% in constant-currency terms.
BDX shares closed up 0.2% at $231.27 apiece yesterday.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.